Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Q3 2019 Earnings Presentation
19 slides from Zealand Pharma A/s's earnings presentation, Nov 15, 2019
Slide 1: Forward-looking statements
Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the inform
Slide 2: Business Highlights
BusinessHighlights Emmanuel Dulac President and Chief Executive Officer 2
Slide 3: A pivotal moment for Zealand Pharma
A pivotal moment for Zealand Pharma Approaching commercialization Establishing operations in the U.S. Accelerating late stage development Robust product pipeline including three late stage programs Establishing our Peptide Platform Founded in 1998 World-leading peptide platform, with two medicines b
Slide 4: Zealand Pharma has made impressive progress in 2019
Zealand Pharma has made impressive progress in 2019 Business highlights in Q3 and the period thereafter • Endpoints achieved in pediatric Phase 3 study with dasiglucagon HypoPal® rescue pen • Initiated Phase 2 clinical proof of concept trial with dasiglucagon in patients with serious meal-induced hy
Slide 5: ZP10000 added to early pipeline through Encycle Therapeutics acquisition
Orally-delivered a4b7 integrin inhibitor (ZP10000) added to early pipeline through Encycle Therapeutics acquisition 47 integrin inhibitor: ZP100001 Encycle Therapeutics acquisition • ZP10000 inhibits integrin 47, which is involved in migration of circulatory pro-inflammatory lymphocytes to intestina
Slide 6: Preparing for commercialization in the U.S.
Preparing for commercialization in the U.S. 2020 U.S. leadership, and key commercial and medical affairs functions onboarded NDA submission for dasiglucagon HypoPal® rescue pen Boston facility opens 6 Glepaglutide for short bowel syndrome DasiglucagonDasiglucagonDasiglucagon HypoPal® Rescue Pen forf
Slide 7: Financial Highlights
Financial Highlights Matt Dallas Chief Financial Officer 7
Slide 8: Maintaining financial strength to support our clinical programs
Maintaining financial strength to support our clinical programs Net Operating Expenses1 Strong cash position R&D and Administrative Expenses DKKm Cash and cash equivalents, restricted cash and marketable securities DKKm $m2 102 $m2 263 233 204 175 146 117 88 58 29 0 1.800 1.600 1.400 1.200 1.000 800
Slide 9: R&D Highlights
R&D Highlights Adam Steensberg Chief Medical & Development Officer 9
Slide 10: Three late stage programs and a promising early pipeline
Three Phase 3 programs and a promising early pipeline Glepaglutide GLP-2 Analog Short bowel syndrome ZP7570 GLP-1/GLP-2 Dual Agonist Short bowel syndrome Dasiglucagon S.C. Continuous Infusion Congenital hyperinsulinism Dasiglucagon Dual-hormone Pump Diabetes management BI 456906 GLP-1/GLU Dual Agoni
Slide 11: Advancing two programs for short bowel syndrome
Advancing two promising programs to address severe unmet medical needs for patients with short bowel syndrome Glepaglutide GLP-2 Analog ZP 7570 GLP-1R/GLP-2R dual agonist Pivotal Phase 3 Phase 1a • Evaluate once-and twice-weekly glepaglutide dosing over 24 weeks Patient enrollment completion expecte
Slide 12: Dasiglucagon HypoPal rescue pen on-track for early 2020 NDA submission
Dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia on-track for early 2020 NDA submission Potential for fastest rescue from hypoglycemia For illustration only Pivotal Phase 31 Confirmatory Phase 33 Pediatric Phase 34 40 min 35 min 30 min 10 min 10 min 10 min 12 min 10 min GlucaGen
Slide 13: Multiple opportunities with dasiglucagon via different product modalities
We are pursuing multiple opportunities to improve modalities patients’ lives with dasiglucagon via different product Dasiglucagon Novel stable glucagon analog Fast onset-of-action Unique stability in liquid formulation Suitable for multiple indications HypoPal® rescue pen for severe hypoglycemia Dua
Slide 14: Expanding treatment opportunities with mini-dose concept for dasiglucagon
Expanding treatment mini-dose concept opportunities for dasiglucagon with a Post-bariatric surgery hypoglycemia (PBH) • Can lead to rapid gastric emptying, hyperinsulinemia and serious hypoglycemia 1-3 hours after food ingestion1 Significant unmet need with currently no approved therapies Estimate o
Slide 15: Boehringer Ingelheim partnership program
Boehringer Ingelheim partnership program: Next generation peptide therapeutics for obesity / type 2 diabetes Long-term partnership to develop two product candidates Study to test whether different doses of BI 456906 are effective in treating adults with Type 2 Diabetes4 BI 456906 GLP-1/glucagon dual
Slide 16: Closing Remarks
Closing Remarks Emmanuel Dulac President and Chief Executive Officer 16
Slide 17: Zealand Pharma in 2019
Zealand Pharma in 2019 First dosing of patients in Patients enrolled in Phase 3 pivotal Phase 3 with dasiglucagon (CHI) extension with glepaglutide (SBS) Phase 1 completion with Collaboration Positive confirmatory Phase Strategic pipeline GLP-1/GLU dual agonist1 between Zealand and Alexion on next g
Slide 18: Q&A and upcoming investor presentations
Q&A presentations Upcoming investor Jefferies Healthcare Conference, London Nordea Innovation Seminar, Stockholm Økonomisk Ugebrev Investor Meeting, Copenhagen November November November 20 26 27 18
Slide 19: Upcoming investor presentations
Upcoming investor presentati Conference, London November 20 ZEALAND PHARMA